Pinealon research monograph — the short-peptide bioregulator

Pinealon belongs to a family of very short peptides — the "peptide bioregulators"
— and the shape of that family's evidence base is the key thing to understand.

Chemical identity & structure.
Pinealon is a synthetic tripeptide — three amino acids (glutamic acid–aspartic
acid–arginine). It is one of a series of short "peptide bioregulators"
associated with a Russian research program, which also includes Epithalon
(covered in Batch 1) and the other bioregulators in this batch.

Mechanism of action.
The proposed mechanism for the short bioregulator peptides — and this should be
read as a hypothesis from a specific research program rather than established
science — is that these very short peptides can interact with DNA and influence
gene expression in a tissue-associated way. For Pinealon the claimed focus is
neuronal tissue, with reported antioxidant and neuroprotective activity. A clear,
independently established receptor mechanism is not part of the evidence base.

Key research findings.
Reported findings include antioxidant effects and protection of neuronal cells
under stress in laboratory models.

The research / citation base.
This is the decisive point. The Pinealon literature is **dominated by a single
Russian research program (the Khavinson group), with very limited
independent replication. Pinealon is not approved** by the FDA or EMA. As
with Epithalon, the marketed claims rest on a research base that has not been
broadly validated by independent, Western-standard studies. Treat it as an
experimental compound with an unverified profile.

Research protocols in the literature.
Research has used injected administration of reconstituted lyophilized peptide,
often in short courses. No independently validated protocol exists.

Quality & sourcing notes.
As a simple tripeptide, Pinealon is straightforward to verify for identity and
purity by COA (mass spectrometry; HPLC). The harder issue is the evidence base,
which no COA addresses.

*Research-use note: Educational summary of published research. Pinealon is not an
approved drug and its evidence base is limited; this is research context only
and not medical advice.*